164 related articles for article (PubMed ID: 31701479)
1. Curative potential of fludarabine, melphalan, and non-myeloablative dosage of busulfan in elderly patients with myeloid malignancy.
Ueda T; Jo T; Okada K; Arai Y; Sato T; Maeda T; Onishi T; Ueda Y
Int J Hematol; 2020 Feb; 111(2):247-255. PubMed ID: 31701479
[TBL] [Abstract][Full Text] [Related]
2. Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation.
Ueda T; Maeda T; Kusakabe S; Fujita J; Fukushima K; Yokota T; Shibayama H; Tomiyama Y; Kanakura Y
Int J Hematol; 2019 Feb; 109(2):197-205. PubMed ID: 30448938
[TBL] [Abstract][Full Text] [Related]
3. Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.
Ishida H; Adachi S; Hasegawa D; Okamoto Y; Goto H; Inagaki J; Inoue M; Koh K; Yabe H; Kawa K; Kato K; Atsuta Y; Kudo K
Pediatr Blood Cancer; 2015 May; 62(5):883-9. PubMed ID: 25545836
[TBL] [Abstract][Full Text] [Related]
4. A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.
Spitzer B; Jakubowski AA; Papadopoulos EB; Fuller K; Hilden PD; Young JW; Barker JN; Koehne G; Perales MA; Hsu KC; van den Brink MR; Kernan NA; Prockop SE; Scaradavou A; Castro-Malaspina H; O'Reilly RJ; Boulad F
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2088-2095. PubMed ID: 28711727
[TBL] [Abstract][Full Text] [Related]
5. Low Incidence of Relapse with a Moderate Conditioning Regimen of Fludarabine, Busulfan, and Melphalan for Patients with Myeloid Malignancies: A Single-Center Analysis of 100 Patients.
Jiang JL; Gao WH; Wang LN; Wan M; Wang L; Hu J
Transplant Cell Ther; 2023 Aug; 29(8):512.e1-512.e8. PubMed ID: 37263418
[TBL] [Abstract][Full Text] [Related]
6. Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia.
DiMaggio E; Zhou JM; Caddell R; Tombleson R; Perkins J; Anasetti C; Khimani F; Pidala J; Nishihori T; Perez L; Betts B; Fernandez HF; Mishra A
Leuk Lymphoma; 2020 Jul; 61(7):1678-1687. PubMed ID: 32133897
[TBL] [Abstract][Full Text] [Related]
7. [A comparison of toxicity and efficacy between busulfan plus fludarabine and busulfan plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia].
Liu H; Fan ZP; Jiang QL; Huang F; Zhou HS; Zhang X; Yu GP; Wu MQ; Sun J; Liu QF
Zhonghua Nei Ke Za Zhi; 2012 Nov; 51(11):880-4. PubMed ID: 23291027
[TBL] [Abstract][Full Text] [Related]
8. Comparison of new flu-bu12-tg conditioning with the standard bu-cy myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia.
Raida L; Tucek P; Faber E; Vondrakova J; Rusinakova Z; Skoumalova I; Hubacek J; Jarosova M; Katrincsakova B; Pikalova Z; Kurfurst P; Indrak K
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Dec; 155(4):327-32. PubMed ID: 22336644
[TBL] [Abstract][Full Text] [Related]
9. Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma.
Ahmed S; Ghosh N; Ahn KW; Khanal M; Litovich C; Mussetti A; Chhabra S; Cairo M; Mei M; William B; Nathan S; Bejanyan N; Olsson RF; Dahi PB; van der Poel M; Steinberg A; Kanakry J; Cerny J; Farooq U; Seo S; Kharfan-Dabaja MA; Sureda A; Fenske TS; Hamadani M
Br J Haematol; 2020 Aug; 190(4):573-582. PubMed ID: 32314807
[TBL] [Abstract][Full Text] [Related]
10. Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia.
Dhere V; Edelman S; Waller EK; Langston A; Graiser M; Connolly EC; Switchenko JM; Esiashvili N; Khan MK
Leuk Lymphoma; 2018 Apr; 59(4):837-843. PubMed ID: 28782395
[TBL] [Abstract][Full Text] [Related]
11. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
[TBL] [Abstract][Full Text] [Related]
12. Reduced-intensity stem cell transplantation for acute myeloid leukemia with fludarabine-based conditioning with intravenous busulfan versus melphalan.
Yamashita T; Takami A; Uchida N; Fukuda T; Eto T; Shiratori S; Ota S; Akasaka T; Miyakoshi S; Kondo T; Hidaka M; Kanda J; Atsuta Y; Yano S
Bone Marrow Transplant; 2020 Oct; 55(10):1955-1965. PubMed ID: 32203256
[TBL] [Abstract][Full Text] [Related]
13. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan.
Shimoni A; Hardan I; Shem-Tov N; Rand A; Herscovici C; Yerushalmi R; Nagler A
Leukemia; 2007 Oct; 21(10):2109-16. PubMed ID: 17690701
[TBL] [Abstract][Full Text] [Related]
14. Impact of Different Fludarabine Doses in the Fludarabine-Based Conditioning Regimen for Unrelated Bone Marrow Transplantation.
Kuriyama K; Fuji S; Ito A; Doki N; Katayama Y; Ohigashi H; Nishida T; Serizawa K; Eto T; Uchida N; Kanda Y; Tanaka M; Matsuoka KI; Nakazawa H; Kanda J; Fukuda T; Atsuta Y; Ogata M
Transplant Cell Ther; 2024 May; 30(5):514.e1-514.e13. PubMed ID: 38373522
[TBL] [Abstract][Full Text] [Related]
15. Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.
Kato K; Yoshida N; Matsumoto K; Matsuyama T
Pediatr Blood Cancer; 2014 Apr; 61(4):712-6. PubMed ID: 24376191
[TBL] [Abstract][Full Text] [Related]
16. Adding melphalan to fludarabine and a myeloablative dose of busulfan improved survival after allogeneic hematopoietic stem cell transplantation in a propensity score-matched cohort of hematological malignancies.
Shimomura Y; Hara M; Yamamoto H; Uchida N; Kawakita T; Ashida T; Takada S; Ikeda T; Morishige S; Maruyama Y; Wake A; Ichinohe T; Fukuda T; Takanashi M; Atsuta Y; Ishikawa T
Bone Marrow Transplant; 2021 Jul; 56(7):1691-1699. PubMed ID: 33658646
[TBL] [Abstract][Full Text] [Related]
17. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
Russell JA; Tran HT; Quinlan D; Chaudhry A; Duggan P; Brown C; Stewart D; Ruether JD; Morris D; Glick S; Gyonyor E; Andersson BS
Biol Blood Marrow Transplant; 2002; 8(9):468-76. PubMed ID: 12374451
[TBL] [Abstract][Full Text] [Related]
18. Favorable Outcome with Conditioning Regimen of Flu/Bu4/Mel in Acute Myeloid Leukemia Patients in Remission Undergoing Cord Blood Transplantation.
Mizuno S; Takami A; Kawamura K; Shimomura Y; Arai Y; Konuma T; Ozawa Y; Sawa M; Ota S; Takahashi S; Anzai N; Hiramoto N; Onizuka M; Nakamae H; Tanaka M; Murata M; Kimura T; Kanda J; Fukuda T; Atsuta Y; Yanada M
Transplant Cell Ther; 2022 Nov; 28(11):775.e1-775.e9. PubMed ID: 35921987
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic Hematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia with a Busulfan, Fludarabine, and Melphalan Regimen: JPLSG JMML-11.
Sakashita K; Yoshida N; Muramatsu H; Ohtsuka Y; Watanabe K; Yabe M; Kakuda H; Honda Y; Watanabe T; Haba M; Ohmori S; Matsuda K; Yuza Y; Saito A; Horibe K; Adachi S; Manabe A
Transplant Cell Ther; 2024 Jan; 30(1):105.e1-105.e10. PubMed ID: 37806448
[TBL] [Abstract][Full Text] [Related]
20. Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing.
Damlaj M; Alkhateeb HB; Hefazi M; Partain DK; Hashmi S; Gastineau DA; Al-Kali A; Wolf RC; Gangat N; Litzow MR; Hogan WJ; Patnaik MM
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1431-1439. PubMed ID: 27164061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
